Clinical Trial Update: Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of the oxidative phosphorylation inhibitor IACS-010759 in relapsed or refractory acute myeloid leukemia has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IACS-010759 (IACS-010759)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2023-06-15